Heron Therapeutics (NASDAQ:HRTX) Shares Gap Up to $3.29

Heron Therapeutics, Inc. (NASDAQ:HRTX) gapped up before the market opened on Friday . The stock had previously closed at $3.29, but opened at $3.37. Heron Therapeutics shares last traded at $3.34, with a volume of 26,557 shares traded.

Analysts Set New Price Targets

HRTX has been the subject of several recent analyst reports. Rodman & Renshaw assumed coverage on shares of Heron Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $7.00 price objective for the company. Capital One Financial assumed coverage on shares of Heron Therapeutics in a research note on Tuesday, April 23rd. They set an “overweight” rating and a $6.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Heron Therapeutics Stock Down 1.8 %

The stock has a market capitalization of $486.60 million, a PE ratio of -5.29 and a beta of 1.81. The stock’s 50 day moving average price is $3.13 and its 200-day moving average price is $2.64.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.06. The firm had revenue of $34.67 million during the quarter, compared to the consensus estimate of $32.50 million. As a group, sell-side analysts predict that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current fiscal year.

Institutional Trading of Heron Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its holdings in shares of Heron Therapeutics by 100.0% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,060,000 after acquiring an additional 1,000,000 shares in the last quarter. Congress Park Capital LLC raised its holdings in Heron Therapeutics by 205.3% in the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock worth $3,058,000 after purchasing an additional 1,209,500 shares in the last quarter. Monaco Asset Management SAM raised its holdings in Heron Therapeutics by 219.5% in the fourth quarter. Monaco Asset Management SAM now owns 2,226,475 shares of the biotechnology company’s stock worth $3,785,000 after purchasing an additional 1,529,567 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in Heron Therapeutics by 49.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 514,377 shares of the biotechnology company’s stock worth $874,000 after purchasing an additional 171,250 shares in the last quarter. Finally, Orchard Capital Management LLC raised its holdings in Heron Therapeutics by 4.7% in the fourth quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock worth $3,814,000 after purchasing an additional 100,603 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.